Project Grant R01HL176793
Award Date
5/15/25
Completion Date
2/28/29
Dollars Obligated
$767K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Augusta, GA 30912, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $732,779 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arizona to investigate the role of the serine-threonine kinase SGK1 in regulating cardiac function and metabolism in cardiometabolic heart failure with preserved ejection fraction (CMET HFPEF). The project aims to determine how cardiac-specific SGK1 influences heart function, metabolism, and inter-organ communication in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of hepatic steatosis (non-alcoholic fatty liver disease) in the development of cardiovascular disease, independent of obesity and metabolic dysfunction. The $604,818 award will fund research to determine if increasing plasma levels of β-hydroxybutyrate (a ketone body) or PPAR-α-regulated hepatokines (nerve growth...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) provides $705,279 to Boston University to investigate the effects of environmental pollutants on the cardiovascular system. The research aims to characterize how lipophilic pollutants and "forever chemicals" impact vascular function, angiogenesis, and inflammation, with a focus on understanding the pathogenic mechanisms involving...
This Project Grant award of $678,803.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research to investigate the role of the mitochondrial deubiquitinase USP30 in regulating cell metabolism, microRNA biogenesis, and microvascular inflammation. The primary research objectives are to determine if inhibiting USP30 in endothelial cells can preserve endothelial barrier function and reduce the severity of acute...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund a multi-omics investigation into the relationship between adiposity (excess body fat) and lipid levels, and their combined impact on cardiovascular disease risk. The $171,450 award, with a period of performance from September 1, 2024 to August 31, 2026, will be used by the lead researcher, Dr. Dron, and her interdisciplinary team at...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the connections between cell metabolism, epigenetic regulation, and the transdifferentiation process that allows fibroblasts to transform into endothelial cells. The $1,245,515.38 award, effective from September 1, 2024 to August 31, 2028, will enable the Methodist Hospital Research Institute (HMRI) to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support a 5-year research study to define the role and mechanistic basis of skeletal muscle actin mutations in dilated cardiomyopathy (DCM). The total funding amount is $171,811, awarded effective July 1, 2024. The principal investigator will establish a multiscale experimental platform utilizing biochemical, biophysical, and in vivo...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $771,750 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism following myocardial infarction. The grant, with an award date of January 1, 2025 and ultimate completion date of November 30, 2028, supports a multi-disciplinary...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to determine how hyperglycemia affects aortic biomechanics and mechanobiology, and whether restoring normoglycemia can reverse these changes. The total funding amount is $126,442, with the award period running from September 1, 2024 to August 31, 2026. The research will be conducted by the Regents of the University of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $104,933 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Duke University. The grant, titled "AGE-RELATED CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IN EXERCISE RESPONSIVENESS", aims to determine the role of the age-related inflammatory biomarker CHIP in cardiorespiratory fitness (CRF) and cardiometabolic responses to chronic exercise training. The research will leverage two...